赛托生物：化学原料药糠酸莫米松上市申请获批

Core Viewpoint - Saito Biopharmaceuticals (300583) announced that its subsidiary, Shandong Sry Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the marketing application of Mometasone Furoate, a potent anti-inflammatory drug [1] Group 1: Product Approval - The approval notification allows for the use of Mometasone Furoate in inhalation and topical formulations [1] - As an inhalation agent, it can be combined with β2-adrenergic agonists and/or long-acting acetylcholine receptor antagonists, primarily for asthma treatment [1] - For topical use, it is indicated for conditions such as eczema, neurodermatitis, atopic dermatitis, and pruritus [1]